Clinical research data sharing promises new cures and treatments

Clinical research generates extensive amounts of data, yet most of it is siloed or generally unavailable to a larger pool of willing potential researchers.

If this data were liberated to the masses, we would venture into a world of endless possibilities where the search for new cures and treatments could be accelerated. From curing cancer to combating cardiovascular disease, clinical research data sharing has the potential to benefit many health care goals.

Clinical research data sharing for cardiovascular scientific discovery
The Duke Clinical Research Institute (DCRI) is at the forefront of this movement to engage in data sharing and research transparency, as noted by Drs. Eric Peterson and Michael Pencina in the short video below.

DCRI is the first academic institution to share their data with the general research community around the world, believing that better, faster and more innovative research will happen if academic institutions share their data.

The DCRI is releasing data from their Duke Databank for Cardiovascular disease. It contains de-identified patient records of more than 100,000 procedures on more than 50,000 patients. Approved researchers will have access to the data to test clinical hypothesis, develop clinical trial protocols and assess long term outcomes and trends.

“Researchers who have good questions can ask questions of that data, analyze it in a protected environment, and ultimately make discoveries that hopefully will help heart disease patients in the future,” says Peterson, in the video.

Results with clinical research data sharing
Secondary analysis of clinical trial research data has already yielded amazing results. For example, Project Datasphere, one of the initiatives of the CEO Roundtable on Cancer, was founded by former President George H.W. Bush who challenged the industry to be “bold and venturesome” in the fight against cancer.

Project Datasphere paved the way to share, integrate and analyze collective cancer research data into one single location and currently contains data from 34,000 patients and a base of more than 1400 researchers accessing the data for new discovery.

So far 15 articles, abstracts and posters based on Project DataSphere data have been accepted by peer reviewed publications. No doubt, this is just the tip of the iceberg. Project Datasphere recognizes that the true power comes from increasing the volume of data about patients, and the group is actively working towards a 100,000-patient goal.

Through Project Datasphere and other programs, clinical trial data sharing is firmly entrenched in the pharmaceutical industry. It is our hope that other academic research institutions follow in the footsteps of the DCRI and Project Datasphere to overcome any internal challenges and liberate historical clinical research on a data sharing platform. We would welcome the opportunity to share our experiences of this voyage of discovery.

Learn how SAS plays a role in the Duke Databank for Cardiovascular Disease

Author: Patrick Homer

Author Img

Patrick Homer leads the Commercial Life Sciences practice at SAS, where he has been responsible for developing a number of advanced analytical applications, such as predictive modeling for physician segmentation, demand forecasting for inventory optimization, social media analytics, master data management for physician spending reporting, visualization of real world data, as well as launch sequence pricing optimization.

Prior to joining SAS, Homer spent 20 years working in the pharmaceutical industry, starting his career in sales, then progressing to running sales teams before moving into business development at Quintiles for sales outsourcing.Clinical research data sharing promises new cures and treatments.

Send Enquiry for this story

By submitting this form you are giving a consent to Worldpharmatoday.com to store your submitted information.
See our Privacy Policy to learn more about how we use data.